Group 1 (PRP) | Group 2 (EGF) | Group 3 (controls) | p | |
---|---|---|---|---|
Assessments at week 6 (mean ± SD) | ||||
Histological CD31 assessment (counts/mm2) | 143.7 ± 8.2 | 151.1 ± 9.2 | 125.2 ± 13.3 | < 0.001 |
Membrane TGF level (ng/mL) | 246.4 ± 54.3 | 257.7 ± 55.2 | 141.8 ± 20.8 | < 0.001 |
Membrane VEGF level (pg/mL) | 842.0 ± 98.5 | 754.8 ± 118.7 | 430.5 ± 92.2 | < 0.001 |
Assessments at week 12 (mean ± SD) | ||||
Histological CD31 assessment (counts/mm2) | 137.3 ± 17.3 | 138.1 ± 14.0 | 99.6 ± 25.5 | 0.003 |
Membrane TGF level (ng/mL) | 397.4 ± 44.4 | 379.3 ± 63.3 | 326.4 ± 42.0 | 0.032 |
Membrane VEGF level (pg/mL) | 318.0 ± 95.2 | 273.0 ± 72.1 | 228.9 ± 44.9 | 0.086 |
Bone VEGF level (pg/mL) | 192.2 ± 6.7 | 198.1 ± 5.7 | 176.3 ± 7.2 | 0.003 |
Bone BMP-2 level (pg/mL) | 191.9 ± 8.4 | 237.6 ± 37.3 | 117.1 ± 43.0 | 0.012 |
Lane score (median, range) | ||||
Anteroposterior | 4 (3-4) | 3 (2-4) | 1 (1-2) | 0.015 |
Lateral | 4 (2-4) | 3.5 (2-4) | 1 (1-2) | 0.026 |
CT | 3 (2-4) | 3 (2-3) | 1 (1-2) | 0.026 |
3D | 3.5 (2-4) | 4 (3-4) | 1.5 (1-3) | 0.044 |